Advanced Recurrent Serous Ovarian Cancer
1 clinical trials · Condition
◉ Watch Advanced Recurrent Serous Ovarian Cancer
| Record | Firm | Date |
|---|---|---|
| First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin (NCT03507452) | Bayer | 2018-06-13 |
Track Advanced Recurrent Serous Ovarian Cancer automatically
Every clearance here is in the API, with alerts when new ones post.